<DOC>
	<DOCNO>NCT00687011</DOCNO>
	<brief_summary>The purpose study determine single intravenous ( IV ) dose palonosetron 0.25 mg plus single IV dose dexamethasone 8 mg effective prevent nausea vomit induce moderately emetogenic chemotherapy subject cancer .</brief_summary>
	<brief_title>Palonosetron Plus Dexamethasone Moderately Emetogenic Chemotherapy Induced Nausea Vomiting ( Study P04594 )</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<mesh_term>Emetics</mesh_term>
	<criteria>Male female , &gt; = 18 year age . Histologically cytologically confirm malignant disease . Naive nonnaive chemotherapy . Karnofsky index &gt; = 70 % . Scheduled receive single dose least one follow agent administer Study Day 1 : dose Dactynomicin , Carboplatin , Epirubicin , Idarubicin , Ifosfamide , Irinotecan , Lomustine ; Methotrexate &gt; 250 mg/m^2 , Cyclophosphamide &lt; =1500 mg/m^2 , Mitoxantrone &lt; 15 mg/m^2 , Doxorubicin &gt; = 20 mg/m^2 , Citarabin &gt; 1g/m^2 , Melphalan &gt; 50 mg/m^2 , oxaliplatin &gt; 75 mg/m^2 administer 1 4 hour . The administration major chemotherapeutic agent ( emetogenic agent accord classification Hesketh , et al. , The Oncologist 1999 , 4 : 191196 ) define Study Day 1 administration agent extend beyond 4 hour . Provided signed write informed consent . Females childbearing potential must use reliable contraceptive measure negative pregnancy test pretreatment visit . If patient know hepatic , renal cardiovascular impairment schedule receive mention chemotherapeutic agent , he/she could enrol study discretion investigator . If patient experience maximum mild nausea follow previous chemotherapy regimen , he/she could enrol study discretion investigator . Unable understand cooperate study procedure . Received investigational drug within 30 day study entry . Received drug potential antiemetic efficacy within 24 hour start treatment schedule receive Study Day 5 include 5HT3 receptor antagonist , metoclopramide , phenothiazine antiemetic ( include prochlorperazine , thiethylperazine perphenazine ) , scopolamine , diphenhydramine , chlorpheniramine maleate , trimethobenzamide , benzodiazepine except temazepam triazolam use nightly sleep , haloperidol , droperidol , tetrahydrocannabinol , nabilone , corticosteroid include dexamethasone , hydrocortisone , methylprednisolone , prednisone ( exclude topical inhale preparation ) . Seizure disorder require anticonvulsant medication unless clinically stable free seizure activity . Experienced vomiting , retch , NCI Common Toxicity Criteria grade 2 3 nausea 24 hour precede chemotherapy . Ongoing vomit organic etiology . Experienced nausea ( moderate severe ) vomit follow previous chemotherapy . At discretion investigator , patient experience maximum mild nausea follow previous chemotherapy might exclude study . Scheduled receive dose cisplatin , carmustine , hexametilamine , dacarbazine , Mecloretamine , Streptozotocin , Procarbazine Cyclophosphamide &gt; 1500 mg/m^2 chemotherapeutic agent emetogenicity level 5 accord classification NCCN Guidelines v1 2005 Study Days 26 . Known contraindication 5HT3 receptor antagonist . Scheduled receive radiotherapy upper abdomen cranium Study Day 26 . QTc &gt; 500 msec baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Antiemetic</keyword>
</DOC>